El-Khoueiry AB, Kim RD, Harris WP, Sung MW, et al. A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma. Hepatology 2025 Nov 10. doi: 10.1097/HEP.0000000000001585.
PMID: 41213032